Latest Market Demand News

Austco Healthcare Limited reported a record $81.4 million in revenue for FY25, driven by organic growth and acquisitions including G&S Technologies. EBITDA jumped 62% to $13 million, reflecting strong operational leverage.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Vulcan Steel Limited reported a 10.9% revenue decline in FY25 alongside a 24.1% drop in adjusted EBITDA, while announcing a fully underwritten NZ$96 million equity raise to fund the acquisition of Roofing Industries Limited. The deal marks Vulcan’s strategic entry into the New Zealand steel roofing and cladding market with expected earnings accretion and no change to its dividend policy.

Cedar Woods Properties Limited reported a robust financial year ending June 2025, with significant increases in revenue, profit, and dividends, underscoring its strong market position.

EVT Group has released an extensive valuation update on its diversified $2.3 billion property portfolio, spotlighting landmark Sydney CBD assets alongside a broad hospitality and entertainment footprint across Australia, New Zealand, and Germany.

Reece Limited reported a modest 1% decline in FY25 sales to $9 billion, with earnings pressured by soft housing markets in Australia and the US. Despite operational investments and branch expansions, the company faces a cautious outlook over the next 12-18 months.

WAM Income Maximiser Limited has reported a profitable first half since its April 2025 IPO, declaring its inaugural fully franked monthly dividend and setting guidance for dividend growth. The company’s diversified portfolio of ASX300 equities and investment grade corporate debt has delivered promising returns, underpinning its income and capital growth objectives.

LTR Pharma has announced that its erectile dysfunction treatment SPONTAN now boasts an 18-month shelf life, surpassing commercial standards and paving the way for international market growth.

Vysarn Limited delivered a robust FY2025 performance, driven by significant acquisitions and expanding operations across Australia’s water infrastructure sector. The company’s strategic moves position it well for sustained growth amid evolving market demands.

Qualitas Limited reported a robust 36% increase in normalised net profit before tax for FY25, driven by strong fee growth and principal income, while guiding for further growth in FY26. The company’s expanding private credit focus and ESG initiatives position it well amid evolving market conditions.

FFI Holdings Limited reported a remarkable 283.5% jump in net profit for FY2025, driven by property revaluations and operational growth, while raising $7.2 million to fund expansion in food manufacturing and property development.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.